Search results
-
Amgen pushes on in Steap1
… therapy. In phase 1 dose-expansion cohorts, presented at ESMO 2024, xaluritamig produced an ORR of 29% with the …
- 11/21/2024 - 16:15 -
Not so fast for Astra in bladder cancer
… Imfinzi (adjuvant), vs chemo Positive data presented at ESMO 2024; filed in EU (decision expected in H2 2025); as of …
- 11/14/2024 - 14:46 -
Triple meeting 2024 – Revolution shows selective KRAS promise
… (solid tumours) Venue Triple meeting 2024 ESMO 2024 ORR 30% (12/40)* 19% (5/27)** …
- 10/31/2024 - 11:10 -
Another hold for BioNTech
… & 2mg/kg Q3W (reduced from 3 & 6mg/kg Q3W) Data at ESMO 2024: ORR 25-28%, Gr≥3 TRAEs 41-46%, discontinuation …
- 10/22/2024 - 13:40 -
Transgene stumbles with its fixed immunotherapy
… in relapsed solid tumours +/- Keytruda Data at ESMO 2024: 2/6 responses with Keytruda combo TG6050 …
- 10/15/2024 - 14:26 -
J&J’s Sunrise dims
… BCG unresponsive +/- cetrelimab vs cetrelimab Data at ESMO 2024: CR 84% vs 46% with TAR-200 mono vs cetrelimab; … cystectomy + cetrelimab vs cetrelimab Data at ESMO 2024: pCR 42% vs 23% with TAR-200 + cetrelimab vs …
- 10/10/2024 - 13:12 -
J&J ramps up its bladder cancer battle
… +/- cetrelimab vs cetrelimab CR Data at ESMO 2024: CR 84% with TAR-200 mono vs 46% with cetrelimab; … cystectomy + cetrelimab vs cetrelimab pCR Data at ESMO 2024: pCR 42% with TAR-200 + cetrelimab vs 23% with …
- 10/09/2024 - 10:09 -
AbbVie has Met phase 3, again
… ORR in high cMet expressers at doses ≥2.4mg/kg); data at ESMO 2024 in GEA (29% ORR) & NSCLC (44% ORR) Ph1 …
- 10/04/2024 - 12:27 -
Shattuck exits oncology
… PD-(L)1-refractory Hodgkin’s lymphoma (Tevimbra combo) at ESMO 2024: 67% ORR (22/33 pts) Lemzoparlimab I-Mab …
- 10/02/2024 - 10:58 -
ESMO 2024 – Regeneron's fianlimab do-over
ESMO 2024 – Regeneron's fianlimab do-over …
- 09/23/2024 - 21:34
